These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25900161)

  • 1. Performance of EUCAST and CLSI approaches for co-amoxiclav susceptibility testing conditions for clinical categorization of a collection of Escherichia coli isolates with characterized resistance phenotypes.
    Díez-Aguilar M; Morosini MI; López-Cerero L; Pascual Á; Calvo J; Martínez-Martínez L; Marco F; Vila J; Ortega A; Oteo J; Cantón R
    J Antimicrob Chemother; 2015 Aug; 70(8):2306-10. PubMed ID: 25900161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consequences of switching from a fixed 2 : 1 ratio of amoxicillin/clavulanate (CLSI) to a fixed concentration of clavulanate (EUCAST) for susceptibility testing of Escherichia coli.
    Leverstein-van Hall MA; Waar K; Muilwijk J; Cohen Stuart J;
    J Antimicrob Chemother; 2013 Nov; 68(11):2636-40. PubMed ID: 23766488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing the validity of different susceptibility testing methods to evaluate the in vitro activity of amoxicillin-clavulanate against Escherichia coli.
    María DA; María-Isabel M; María-Carmen C; Álvaro P; Jorge C; Luis MM; Francesc M; Jordi V; Adriana O; Jesús O; Rafael C
    Diagn Microbiol Infect Dis; 2016 Apr; 84(4):334-6. PubMed ID: 26830054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae.
    Delgado-Valverde M; Valiente-Mendez A; Torres E; Almirante B; Gómez-Zorrilla S; Borrell N; Aller-García AI; Gurgui M; Almela M; Sanz M; Bou G; Martínez-Martínez L; Cantón R; Antonio Lepe J; Causse M; Gutiérrez-Gutiérrez B; Pascual Á; Rodríguez-Baño J;
    J Antimicrob Chemother; 2017 May; 72(5):1478-1487. PubMed ID: 28093484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility testing of Escherichia coli isolates from urines: are we at risk of reporting false antibiotic resistance to co-amoxiclav?
    Bond A; Plumb H; Turner P
    J Antimicrob Chemother; 2012 Jun; 67(6):1557-8. PubMed ID: 22334608
    [No Abstract]   [Full Text] [Related]  

  • 7. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of E. coli susceptibility for amoxicillin/clavulanic acid according to EUCAST and CLSI guidelines.
    Vanstokstraeten R; Belasri N; Demuyser T; Crombé F; Barbé K; Piérard D
    Eur J Clin Microbiol Infect Dis; 2021 Nov; 40(11):2371-2377. PubMed ID: 34175999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines for the interpretation of antibiotic susceptibility at a University teaching hospital in Nairobi, Kenya: a cross-sectional study.
    Kassim A; Omuse G; Premji Z; Revathi G
    Ann Clin Microbiol Antimicrob; 2016 Apr; 15():21. PubMed ID: 27068515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in Escherichia coli causing bacteraemia.
    van der Bij AK; van Dijk K; Muilwijk J; Thijsen SF; Notermans DW; de Greeff S; van de Sande-Bruinsma N;
    Clin Microbiol Infect; 2012 Nov; 18(11):E466-72. PubMed ID: 22925456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Picón E; Navarro MD; López-Cerero L; Pascual A;
    Clin Microbiol Infect; 2012 Sep; 18(9):894-900. PubMed ID: 21985560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of Escherichia coli to the amoxycillin-clavulanate combination: which recommendations should be used to provide relevant information to clinicians?
    Patry I; Hocquet D; Talon D; Plesiat P; Bertrand X
    Clin Microbiol Infect; 2005 Mar; 11(3):237-40. PubMed ID: 15715724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin.
    Docobo-Pérez F; Fernández-Cuenca F; Pachón-Ibáñez ME; Pascual A; Pichardo C; Martínez-Martínez L; Pachón J
    Clin Microbiol Infect; 2008 Jun; 14(6):582-7. PubMed ID: 18294246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Area of technical uncertainty for susceptibility testing of amoxicillin/clavulanate against Escherichia coli: analysis of automated system, Etest and disk diffusion methods compared to the broth microdilution reference.
    Soares A; Pestel-Caron M; Leysour de Rohello F; Bourgoin G; Boyer S; Caron F
    Clin Microbiol Infect; 2020 Dec; 26(12):1685.e1-1685.e6. PubMed ID: 32151599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconciling the Potentially Irreconcilable? Genotypic and Phenotypic Amoxicillin-Clavulanate Resistance in
    Davies TJ; Stoesser N; Sheppard AE; Abuoun M; Fowler P; Swann J; Quan TP; Griffiths D; Vaughan A; Morgan M; Phan HTT; Jeffery KJ; Andersson M; Ellington MJ; Ekelund O; Woodford N; Mathers AJ; Bonomo RA; Crook DW; Peto TEA; Anjum MF; Walker AS
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32205351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Haemophilus influenzae EUCAST and CLSI disc diffusion methods to recognize aminopenicillin and amoxicillin/clavulanate resistance.
    Fernando SA; Pang S; McKew GL; Phan T; Merlino J; Coombs GW; Gottlieb T
    J Antimicrob Chemother; 2020 Sep; 75(9):2594-2598. PubMed ID: 32585694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the comparability of CLSI, EUCAST and Stokes antimicrobial susceptibility profiles for Escherichia coli uropathogenic isolates.
    O'Halloran C; Walsh N; O'Grady MC; Barry L; Hooton C; Corcoran GD; Lucey B
    Br J Biomed Sci; 2018 Jan; 75(1):24-29. PubMed ID: 29210602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
    Pottumarthy S; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Nov; 53(3):225-31. PubMed ID: 16257168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility to amoxycillin-clavulanate among clinical isolates of Escherichia coli resistant to cefoxitin.
    Fernandez-Cuenca F; Martinez-Martinez L; Amblar G; Biedenbach DJ; Jones RN; Pascual A
    Clin Microbiol Infect; 2006 Feb; 12(2):197-8. PubMed ID: 16441464
    [No Abstract]   [Full Text] [Related]  

  • 20. Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration.
    Alou L; Aguilar L; Sevillano D; Giménez MJ; Cafini F; Valero E; Relaño MT; Prieto J
    J Antimicrob Chemother; 2006 Apr; 57(4):714-9. PubMed ID: 16492718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.